Goldman Sachs Resumes Coverage of Illumina | GenomeWeb

Goldman Sachs Resumes Coverage of Illumina

May 03, 2012

|

NEW YORK (GenomeWeb News) – Investment bank Goldman Sachs has reinstated coverage of Illumina, giving it a Neutral rating and a 12-month price target on its stock of $48.

The bank suspended coverage of Illumina shortly after Roche launched its hostile bid for the San Diego firm. Goldman Sachs was an advisor to Illumina on the proposed deal, which ended when Roche abandoned its pursuit last month.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

And Deal

Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.

For Long Life

Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.

Positive Review

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

This Week in Nucleic Acids Research

In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.